Formulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuria

Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein

(2015) Yu Mima et al.   MOLECULAR PHARMACEUTICS

Anti-PEG immunity: emergence, characteristics, and unaddressed questions

(2015) Qi Yang et al.   Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology

Arrhenius Time-Scaled Least Squares: A Simple, Robust Approach to Accelerated Stability Data Analysis for Bioproducts

(2014) Adam P. Rauk et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Biotechnological production and applications of microbial phenylalanine ammonia lyase: a recent review

(2013) Jian Dong Cui et al.   CRITICAL REVIEWS IN BIOTECHNOLOGY

Phenylalanine hydroxylase deficiency

(2011) John J. Mitchell et al.   GENETICS IN MEDICINE

Up to date knowledge on different treatment strategies for phenylketonuria

(2011) Amaya Bélanger-Quintana et al.   MOLECULAR GENETICS AND METABOLISM

Optimizing the use of sapropterin (BH4) in the management of phenylketonuria

(2009) Nenad Blau et al.   MOLECULAR GENETICS AND METABOLISM

Structural and Biochemical Characterization of the Therapeutic Anabaena variabilis Phenylalanine Ammonia Lyase

(2008) Lin Wang et al.   JOURNAL OF MOLECULAR BIOLOGY

Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria

(2008) C. N. Sarkissian et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency

(2007) Marcel R. Zurflüh et al.   HUMAN MUTATION